560 related articles for article (PubMed ID: 26810975)
1. Integrating mutation and gene expression cross-sectional data to infer cancer progression.
Fleck JL; Pavel AB; Cassandras CG
BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous inference of cancer pathways and tumor progression from cross-sectional mutation data.
Raphael BJ; Vandin F
J Comput Biol; 2015 Jun; 22(6):510-27. PubMed ID: 25785493
[TBL] [Abstract][Full Text] [Related]
3. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data.
Zhang J; Zhang S; Wang Y; Zhang XS
BMC Syst Biol; 2013; 7 Suppl 2(Suppl 2):S4. PubMed ID: 24565034
[TBL] [Abstract][Full Text] [Related]
4. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
Pavel AB; Sonkin D; Reddy A
BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
[TBL] [Abstract][Full Text] [Related]
5. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
7. Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer.
Narayan S; Bader GD; Reimand J
Genome Med; 2016 May; 8(1):55. PubMed ID: 27175787
[TBL] [Abstract][Full Text] [Related]
8. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
9. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
[TBL] [Abstract][Full Text] [Related]
10. ZDOG: zooming in on dominating genes with mutations in cancer pathways.
Alberts R; Chen J; Zhang L
BMC Bioinformatics; 2019 Dec; 20(1):740. PubMed ID: 31888434
[TBL] [Abstract][Full Text] [Related]
11. Identifying cancer type specific oncogenes and tumor suppressors using limited size data.
Pavel AB; Vasile CI
J Bioinform Comput Biol; 2016 Dec; 14(6):1650031. PubMed ID: 27712196
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
Wu G; Xing M; Mambo E; Huang X; Liu J; Guo Z; Chatterjee A; Goldenberg D; Gollin SM; Sukumar S; Trink B; Sidransky D
Breast Cancer Res; 2005; 7(5):R609-16. PubMed ID: 16168105
[TBL] [Abstract][Full Text] [Related]
13. Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration.
Verbeke LP; Van den Eynden J; Fierro AC; Demeester P; Fostier J; Marchal K
PLoS One; 2015; 10(7):e0133503. PubMed ID: 26217958
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of somatic mutations and transcriptomic data to functionally stratify breast cancer patients.
Zhang J; Abrams Z; Parvin JD; Huang K
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):513. PubMed ID: 27556157
[TBL] [Abstract][Full Text] [Related]
15. Discovery of mutated subnetworks associated with clinical data in cancer.
Vandin F; Clay P; Upfal E; Raphael BJ
Pac Symp Biocomput; 2012; ():55-66. PubMed ID: 22174262
[TBL] [Abstract][Full Text] [Related]
16. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
17. Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis.
Zhang Y; Yang W; Li D; Yang JY; Guan R; Yang MQ
BMC Med Genomics; 2018 Nov; 11(Suppl 5):104. PubMed ID: 30454048
[TBL] [Abstract][Full Text] [Related]
18. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
Kim D; Li R; Dudek SM; Ritchie MD
J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
[TBL] [Abstract][Full Text] [Related]
19. Identification of constrained cancer driver genes based on mutation timing.
Sakoparnig T; Fried P; Beerenwinkel N
PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
